首页> BMC public health> Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study.

Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study.

导出 OA

翻译打印收藏纠错

第一作者： Liangwen,Zhang

第一单位： State Key Laboratory of Vaccines for Infectious Diseases，Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China.;Key Laboratory of Health Technology Assessment of Fujian Province University, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China.

作者： Liangwen,Zhang ^[1] ; Yanhui,Zhang ^[1] ; Xiaoxuan,Wang ^[1] ; Chaobin,Tang ^[1] ; Ya,Fang ^[2]

作者单位： State Key Laboratory of Vaccines for Infectious Diseases，Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China.;Key Laboratory of Health Technology Assessment of Fujian Province University, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China. ^[1] State Key Laboratory of Vaccines for Infectious Diseases，Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China. fangya@xmu.edu.cn.;Key Laboratory of Health Technology Assessment of Fujian Province University, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, People's Republic of China. fangya@xmu.edu.cn. ^[2]

关键词 Cervical cancer Economic evaluation Human papillomavirus vaccine Screening